It is a phase 2, multinational, open-label, single-arm trial on resected stage II to IIIB NSCLC patients with common (exon 19 deletion or L858R) or uncommon (G719X, L861Q, and/or S768I) EGFR-TKI sensitizing mutations. Here, EGFR is linked to non-small cell lung carcinoma.